|
|||||
|
|
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas |
|
| Authors: | Javier Hernández‐Losa PhD Sara Simonetti MD Claudia Valverde MD Teresa Moliné BS Rosa Somoza BS Manuel Pérez MD Roberto Vélez MD PhD Ramona Vergés MD PhD Rosa Domínguez MD Joan Carles MD PhD Santiago Ramón y Cajal MD PhD |
| Affiliation: | 1. Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain;2. Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain;3. Department of Orthopedic Surgery, Vall d'Hebron University Hospital, Barcelona, Spain;4. Department of Radiotherapy, Vall d'Hebron University Hospital, Barcelona, Spain;5. Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain |
| Abstract: | |
| Keywords: | KRAS outcomes phosphoinositide 3‐kinase inhibitor (PI3K)/mammalian target of rapamycin (mTOR) pathway RAS/mitogen‐activated protein kinases (MAPK) pathway undifferentiated pleomorphic sarcoma |